Sofosbuvir

Hepcinat

Indication:

Hepcinat (Sofosbuvir 400mg) is a prescription medicine used with other antiviral medicines to treat adults with chronic hepatitis C (Hep C) with or without cirrhosis (compensated). Hepcinat recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, daclatasvir, or velpatasvir to cure genotype 1 to 6 infections. Cure rates are 30 to 97% depending on the type of hepatitis C virus involved.

Hepcinat (Sofosbuvir 400mg) is a substrate of P-glycoprotein, a transporter protein that pumps drugs and other substances from intestinal epithelium cells back into the gut. Therefore, inducers of intestinal P-glycoprotein, such as rifampicin and St. John's wort, could reduce the absorption of Hepcinat. In addition, coadministration of Hepcinat with anticonvulsants (carbamazepine, phenytoin, phenobarbital, oxcarbazepine), antimycobacterials (rifampin, rifabutin, rifapentine), and the HIV protease inhibitor tipranavir and ritonavir is expected to decrease Hepcinat concentration. Thus, coadministration is not recommended.

Hepcinat may reactivate hepatitis B in those who have been previously infected. In combination with ledipasvir, daclatasvir or simeprevir it is not recommended with amiodarone due to the risk of an abnormally slow heartbeat.Hepcinat (Sofosbuvir 400mg) alone has been assigned a Pregnancy Category B by the FDA (meaning that it there are no adequate and well-controlled studies in pregnant women but animal reproduction studies have not demonstrated a risk to the fetus and, or that adverse effects have been seen in animal studies, but adequate and well-controlled studies in pregnant women have not, in any trimester). However, ribavirin, a medication that is often given together with Hepcinat to treat hepatitis C, is assigned a Pregnancy Category X (contraindicated in pregnancy) by the FDA. Pregnant women with hepatitis C who take ribavirin have shown some cases of birth defects and death in their fetus.


Brand name:Hepcinat

Active Ingeridents: Sofosbuvir-400MG

Company Name: Natco

Package: 28 tabs/bottle

Strength : 400Mg

Sofosbuvir Mechanism of action:

Sofosbuvir is a prodrug using the ProTide biotechnology strategy. It is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate. The triphosphate serves as a faulty substrate for the NS5B protein, which is the viral RNA polymerase, accordingly goes about as an inhibitor of viral RNA combination.In spite of the fact that sofosbuvir has a 3’ hydroxyl gathering to go about as a nucleophile for an approaching NTP, a comparative nucleotide simple, 2’- deoxy-2’- α-fluoro-β-C-methylcytidine, is proposed to go about as a chain eliminator on the grounds e causes a steric clash with an incoming NTP. Sobosbuvir would act in a similar way. Before the disclosure of sofosbuvir, an assortment of nucleoside analogs had been analyzed as antihepatitis C medicines, yet these showed moderately low power. This low intensity emerges to a limited extent in light of the fact that the enzymatic expansion of the first of the three phosphate gatherings of the triphosphate is moderate. The plan of sofosbuvir, in light of the protide approach, stays away from this moderate stride by building the main phosphate aggregate into the structure of the medication amid union. Extra gatherings are appended to the phosphorus to briefly veil the two negative charges of the phosphate assemble, accordingly encouraging passage of the medication into the contaminated cell. The NS5B protein is a RNA-subordinate RNA polymerase basic for the viral multiplication cycle. Sofosbuvir and other nucleotide inhibitors of the HCV RNA polymerase exhibit a very high barrier to resistance development. This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid resistance development has proved to be an important cause of therapeutic failure.

The recommended daily dose of Hepcinat (Sofosbuvir) is 400mg tablet to be taken once daily with or without food.Hepcinat(Sofosbuvir) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.

Store:

Store at 25°C in a dry place.

Sofosbuvir Side effects:

The following serious adverse reactions are described below and elsewhere in the labeling:

  • Serious Symptomatic Bradycardia When Coadministered with Amiodarone and Another HCV Direct Acting Antiviral [see WARNINGS AND PRECAUTIONS]. Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. When HEPCINAT is administered with ribavirin or peginterferon alfa/ribavirin, refer to the respective prescribing information for a description of adverse reactions associated with their use.

Sofosbuvir Precaution:

Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.

Warning

Hepcinat (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.